VRNA vs. CYBR
VRNA (Verona Pharma plc) and CYBR (CyberArk Software Ltd.) are both stocks. VRNA operates in Biotechnology (Healthcare), while CYBR operates in Software - Infrastructure (Technology). At a 0.16 correlation, their price movements are largely independent.
Performance
VRNA vs. CYBR - Performance Comparison
Loading charts...
Returns By Period
VRNA
- 1D
- —
- 1M
- —
- YTD
- —
- 6M
- —
- 1Y
- —
- 3Y*
- —
- 5Y*
- —
- 10Y*
- —
CYBR
- 1D
- —
- 1M
- —
- YTD
- —
- 6M
- —
- 1Y
- —
- 3Y*
- —
- 5Y*
- —
- 10Y*
- —
VRNA vs. CYBR - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
VRNA Verona Pharma plc | 0.00% | 130.21% | 133.60% | -23.92% | 288.84% | -4.00% | 21.74% | -40.41% | -18.71% | -12.07% |
CYBR CyberArk Software Ltd. | -8.34% | 33.89% | 52.09% | 68.95% | -25.18% | 7.23% | 38.61% | 57.24% | 79.13% | -21.40% |
Correlation
The correlation between VRNA and CYBR is 0.16, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.16 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.17 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.20 |
Correlation (All Time) Calculated using the full available price history since Apr 27, 2017 | 0.16 |
Fundamentals
VRNA:
$9.72B
CYBR:
$20.69B
VRNA:
-$0.69
CYBR:
-$2.92
VRNA:
57.97
CYBR:
15.13
VRNA:
34.92
CYBR:
8.61
VRNA:
$167.65M
CYBR:
$1.36B
VRNA:
$159.52M
CYBR:
$1.01B
VRNA:
-$40.86M
CYBR:
$59.13M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
VRNA vs. CYBR - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Verona Pharma plc (VRNA) and CyberArk Software Ltd. (CYBR). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
Risk / return metrics aren't available yet — we need at least 12 months of trading data to calculate them.
Loading charts...
Drawdowns
VRNA vs. CYBR - Drawdown Comparison
Loading charts...
Volatility
VRNA vs. CYBR - Volatility Comparison
Loading charts...
Dividends
VRNA vs. CYBR - Dividend Comparison
Neither VRNA nor CYBR has paid dividends to shareholders.
Financials
VRNA vs. CYBR - Financials Comparison
This section allows you to compare key financial metrics between Verona Pharma plc and CyberArk Software Ltd.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
VRNA vs. CYBR - Profitability Comparison
VRNA - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Verona Pharma plc reported a gross profit of 71.68M and revenue of 75.14M. Therefore, the gross margin over that period was 95.4%.
CYBR - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, CyberArk Software Ltd. reported a gross profit of 267.25M and revenue of 372.65M. Therefore, the gross margin over that period was 71.7%.
VRNA - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Verona Pharma plc reported an operating income of 9.69M and revenue of 75.14M, resulting in an operating margin of 12.9%.
CYBR - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, CyberArk Software Ltd. reported an operating income of 1.75M and revenue of 372.65M, resulting in an operating margin of 0.5%.
VRNA - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Verona Pharma plc reported a net income of 8.69M and revenue of 75.14M, resulting in a net margin of 11.6%.
CYBR - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, CyberArk Software Ltd. reported a net income of -17.11M and revenue of 372.65M, resulting in a net margin of -4.6%.
Frequently Asked Questions
VRNA and CYBR have a correlation of 0.16, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
Find the right allocation for VRNA and CYBR
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer